PHOTO
UAE Vision 2021 National Agenda for Health to use the medical technologies supported by Artificial Intelligence.
Dubai, UAE: Al Zahra Hospital Dubai (AZHD), striving to embody the principles propagated by the ‘UAE Vision 2021 National Agenda for Health’, is aiming to be one of the early adopters of Artificial Intelligence (AI) backed technologies. To fast-track this process, AZHD has further strengthened its partnership with Siemens Healthineers, one of the largest healthcare providers in the world.
Healthcare specialists are often challenged with unwanted variability and inconsistent results, when people of different physiologies and anatomies are examined during MRI examinations and ultrasound imaging. In an attempt to overcome these challenges, clinicians have traditionally compromised on ultrasound image resolution, or penetration of their ultrasound imaging.
“Around 47.5 percent of UAE residents are overweight, and close to 13 percent are obese. To address this challenge on an urgent basis, AZHD’s adoption of Siemens Healthineers’ newly released ACUSON Sequoia ultrasound system, with its higher penetration capabilities, now equips the hospital to accurately diagnose patients with larger body types,” stated Dr. Mohaymen Abdelghany, CEO of Al Zahra Hospital Dubai (AZHD).
ACUSON Sequoia’s new BioAcoustic imaging technology accurately represents human biology and tracks the ultrasound signal throughout the signal path for a high quality image.
“AZHD will be one of the early adopters in the UAE to install the state-of-the-art high-tech MRI and Ultrasound systems to provide accurate diagnostic support to its different current and future certified centers of excellence in AZHD such as orthopaedics and sports injuries, bariatrics and metabolic surgery, minimally invasive gynaecology, oncology and cardiology in a major step to pursue our vision of leading the region in clinical outcome and patient experience.
Fast MRI sequences and protocols will enable AZHD to increase imaging quality, minimize post-surgical image discrepancy from 8 to 2% and achieve its same day MRI objective by reducing the MRI wait list. An additional 20 patients will benefit daily from the latest MRI MAGNETOM Vida equipped with the BioMatrix artificial intelligence technology,” added Dr. Mohaymen.
The MAGNETOM Vida, aims to personalise MRI scans by overcoming patient biovariability, that is the individual’s unique characteristics rather than being seen as an impediment when it comes to MRI scanning. MAGNETOM Vida with BioMatrix Technology gives reproducible image quality and comprehensive clinical information irrespective of the patient or system operator.
Unrestricted 2
"We have long years of experience in healthcare and are proud of the high standard of healthcare service we provide. Our philosophy is patient-centric care and focus on the clinical outcome. We are excited about the plans to continue the growth of our hospital, emphasizing our commitment to provide the best healthcare to our community,” added Dr. Mohaymen.
Ole Maloy, Managing Director, Siemens Healthineers Middle East and Southern and Eastern Africa, “Improving patient experience is an integral part of our company values and is deeply embedded within our DNA. At Siemens Healthineers, our mission is to enable healthcare providers to deliver high-value care. We are extremely proud to collaborate with Al Zahra Hospital Dubai by providing them with innovative technology and supporting them in their journey to provide the best healthcare for UAE.”
© Press Release 2019Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
